Medicare AdvantageCoverageLow impact
MA08.155b, Spesolimab-sbzo (Spevigo®)
Independence Blue Cross·Dermatology, Rheumatology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.155b for Spesolimab-sbzo (Spevigo®) has been reissued and will become effective May 28, 2025. This is a pharmacy policy update that may affect coverage criteria, prior authorization requirements, or billing procedures for this specialty medication used to treat pustular psoriasis.
Action Required
By May 28, 2025: Billing team should review the full policy details at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Spesolimab-sbzo (Spevigo®). Update billing system and provider workflows accordingly based on the specific policy changes identified.